Dr. Iveson on the IDEA Collaboration in CRC

Tim Iveson, MD, FACP
Published: Wednesday, Aug 14, 2019



Tim Iveson, MD, FACP, medical oncologist, University Hospital Southampton NHS Foundation Trust, discusses the International Duration Evaluation of Adjuvant Chemotherapy Collaboration, which examines the effects of adjuvant oxaliplatin-based therapy given for 3 months versus 6 months in patients with high-risk stage II colorectal cancer.

In the trial, 3273 patients received CAPOX or FOLFOX, which was decided by the treating physician. Patients were then randomized to receive the chemotherapy for 3 months versus 6 months.

Results showed there were more adverse events (AEs) in patients who received 6 months of treatment versus patients who received 3 months of treatment across all AEs, particularly diarrhea and peripheral neuropathy. The rate of peripheral neuropathy in patients with 3 months of treatment was 13.0% versus 36% in patients who received 6 months treatment. Additionally, 5-year disease-free survival, which was the primary endpoint, was 80.7% for patients who received 3 months of chemotherapy versus 83.9% for patients who received 6 months of chemotherapy.
SELECTED
LANGUAGE


Tim Iveson, MD, FACP, medical oncologist, University Hospital Southampton NHS Foundation Trust, discusses the International Duration Evaluation of Adjuvant Chemotherapy Collaboration, which examines the effects of adjuvant oxaliplatin-based therapy given for 3 months versus 6 months in patients with high-risk stage II colorectal cancer.

In the trial, 3273 patients received CAPOX or FOLFOX, which was decided by the treating physician. Patients were then randomized to receive the chemotherapy for 3 months versus 6 months.

Results showed there were more adverse events (AEs) in patients who received 6 months of treatment versus patients who received 3 months of treatment across all AEs, particularly diarrhea and peripheral neuropathy. The rate of peripheral neuropathy in patients with 3 months of treatment was 13.0% versus 36% in patients who received 6 months treatment. Additionally, 5-year disease-free survival, which was the primary endpoint, was 80.7% for patients who received 3 months of chemotherapy versus 83.9% for patients who received 6 months of chemotherapy.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication
x